Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a new target complex for treatment of autoimmune and inflammatory diseases-proof of concept in a mouse model of colitis.
Bank
Ute
U
IMTM 2 tto-von-Guericke-University Magdeburg, L 39120 Magdeburg, Germany.
Tadje
Janine
J
Helmuth
Martin
M
Stefin
Sofia
S
Täger
Michael
M
Wolke
Carmen
C
Wischeropp
Anke
A
Ittenson
Annelore
A
Reinhold
Dirk
D
Ansorge
Siegfried
S
Lendeckel
Uwe
U
D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy*; D018826:CD13 Antigens / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000502:physiology; D003092:Colitis / Q000139:chemically induced / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007249:Inflammation / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008807:Mice, Inbred BALB C; D011480:Protease Inhibitors / Q000378:metabolism; D015375:Receptors, Interleukin-2 / Q000276:immunology
D011480:Protease Inhibitors; D015375:Receptors, Interleukin-2; D018826:CD13 Antigens; D018819:Dipeptidyl Peptidase 4